NDC 50090-0169-01 - Orphenadrine Citrate
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 50090-0169
- Requested NDC
- 50090-0169-01
- Package NDCs from labels
- 50090-0169-0, 50090-0169-1, 50090-0169-2, 50090-0169-5, 50090-0169-01
- Manufacturer
- A-S Medication Solutions
- Effective date
- 2026-01-20
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Orphenadrine Citrate - A-S Medication Solutions | A-S Medication Solutions | 2026-01-20 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50090-0169-0 | Orphenadrine Citrate | 20 in 1 BOTTLE | TABLET, EXTENDED RELEASE | 20 | 19 | |
| 50090-0169-1 | Orphenadrine Citrate | 30 in 1 BOTTLE | TABLET, EXTENDED RELEASE | 30 | 19 | |
| 50090-0169-2 | Orphenadrine Citrate | 14 in 1 BOTTLE | TABLET, EXTENDED RELEASE | 14 | 19 | |
| 50090-0169-5 | Orphenadrine Citrate | 60 in 1 BOTTLE | TABLET, EXTENDED RELEASE | 60 | 19 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50090-0169 | ORPHENADRINE CITRATE TABLET, EXTENDED RELEASE [A-S MEDICATION SOLUTIONS] | 17 | Current NDC, Legacy NDC, 4 package rows | 20231204_80ef7fb4-7c50-4d25-915e-f9d4a2ccd199.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50090-0169-0 | EA - Each | 50090-0169 | 8d113a9c-ac81-480d-8b7d-2c1cbc2a9a3e | 1 | 2018-08-13 |
| 50090-0169-1 | EA - Each | 50090-0169 | 05646391-f849-481e-941d-bf62a5bb1a8d | 1 | 2018-08-13 |
| 50090-0169-2 | EA - Each | 50090-0169 | 29b136af-8ccb-42cb-9790-ba341f92f4ab | 1 | 2018-08-13 |
| 50090-0169-5 | EA - Each | 50090-0169 | a83b1cdd-583f-4fd5-8337-0d90a87e252f | 1 | 2018-08-13 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Rohto All-In-One | HYPROMELLOSE, TETRAHYDROZOLINE HYDROCHLORIDE, ZINC SULFATE | The Mentholatum Company | 43e690e4-b381-46e3-838c-33aef5bdadde | 2026-08-20 | Warnings | 3NXW29V3WO |
| Leader Dry Eye Relief Eye Drops | GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 | CARDINAL HEALTH 110, LLC. DBA LEADER | 2ded4bda-b3c3-4521-8701-5c8446fd148b | 2026-08-17 | Warnings | 3NXW29V3WO |
| Dr. Shitong Photon Energy Eye Care Liquid | TETRAHYDROZOLINE HCL 0.05% HYPROMELLOSE 0.3% DR. SHITONG PHOTON ENERGY EYE CARE LIQUID | Wenzhou Yuyuan Pharmaceutical Co., Ltd. | 58ace434-55ef-17ef-e063-6294a90aa878 | 2026-08-10 | Warnings | 3NXW29V3WO |
| ORPHENADRINE CITRATE | ORPHENADRINE CITRATE | REMEDYREPACK INC. | 7905e80f-b60b-48e8-8e63-a3e50211bfe4 | 2026-08-10 | Warnings, Adverse reactions | ANDA040284 994521 X0A40N8I4S |
| Orphenadrine Citrate | ORPHENADRINE CITRATE | Preferred Pharmaceuticals, Inc. | 8ca9438d-320f-4499-aee7-6b8ca7cccc65 | 2026-08-07 | Warnings, Adverse reactions | ANDA040284 994521 X0A40N8I4S |
| Artificial Tears | ARTIFICIAL TEARS | AvPAK | f18bebf2-1936-658f-e053-2a95a90a5012 | 2026-07-07 | Warnings | 3NXW29V3WO |
| Orphenadrine Citrate | ORPHENADRINE CITRATE | St. Mary's Medical Park Pharmacy | 59000b66-166e-75d2-e053-2a91aa0af3c0 | 2026-06-26 | Warnings, Adverse reactions | ANDA040284 994521 X0A40N8I4S |
| Rohto Sun and Sport | HYPROMELLOSE, POVIDONE | The Mentholatum Company | 8bcc8882-b886-4b55-9bc4-d4b92a41358f | 2026-06-19 | Warnings | 3NXW29V3WO |
| Rohto Dual Light Relief | HYPROMELLOSE, POVIDONE | The Mentholatum Company | 1b597f83-d7f1-cf93-e063-6394a90a99f7 | 2026-06-19 | Warnings | 3NXW29V3WO |
| Rohto Digi-Eye | HYPROMELLOSE, TETRAHYDROZOLINE HYDROCHLORIDE | The Mentholatum Company | 5d6f37b9-b568-4cb6-92de-eb40779f3f8c | 2026-06-03 | Warnings | 3NXW29V3WO |
| Exovisse Preservative-Free Artificial Tears | LUBRICANT EYE GEL DROPS | YD BIO USA, INC. | 4f20191a-9124-2525-e063-6294a90a8428 | 2026-04-10 | Warnings | 3NXW29V3WO |
| LensMate Preservative-Free Artificial Tears | LUBRICANT EYE DROPS | YD BIO USA, INC. | 4ebacb2b-9b2d-6bc1-e063-6294a90a3426 | 2026-04-05 | Warnings | 3NXW29V3WO |
| Exovisse Preservative-Free Artificial Tears | LUBRICANT EYE GEL DROPS | YD BIO USA, INC. | 4ebc154b-128b-9dde-e063-6294a90ae00e | 2026-04-05 | Warnings | 3NXW29V3WO |
| Crocodile Tears Lubricant Eye Drops | GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 | Crocodile Tears LLC | 4df29336-ea0c-0484-e063-6294a90a685a | 2026-03-26 | Warnings | 3NXW29V3WO |
| Artificial Tears Lubricant Eye Drops | GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 | KC Pharmaceuticals, Inc | 4de5c844-85ca-ff9f-e063-6394a90ac12c | 2026-03-25 | Warnings | 3NXW29V3WO |
| Artificial Tears | GLYCERIN | Preferred Pharmaceuticals Inc. | dd646c72-8f47-43c6-a734-db0dcc8cd4d1 | 2026-03-06 | Warnings | 3NXW29V3WO |
| ORPHENADRINE CITRATE | ORPHENADRINE CITRATE | Bryant Ranch Prepack | 1b4e379e-8051-421f-a0f4-ad9e6fb9476a | 2026-02-26 | Warnings, Adverse reactions | ANDA040284 994521 X0A40N8I4S |
| Orphenadrine Citrate | ORPHENADRINE CITRATE | A-S Medication Solutions | 80ef7fb4-7c50-4d25-915e-f9d4a2ccd199 | 2026-01-20 | Warnings, Adverse reactions | ANDA040284 50090-0169-1 50090-0169-5 50090-0169-0 50090-0169-2 50090-0169 50090016901 994521 a11270c6-fe5e-4cfd-9a1e-f11abb0fe4a0 80ef7fb4-7c50-4d25-915e-f9d4a2ccd199 X0A40N8I4S |
| Norgesic | ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE | Galt Pharmaceuticals, LLC | be2761bc-e537-4039-846a-2ffa3d8b2afc | 2026-01-08 | Warnings, Adverse reactions | X0A40N8I4S |
| ORPHENADRINE CITRATE | ORPHENADRINE CITRATE | PD-Rx Pharmaceuticals, Inc. | 87d78229-f022-4b42-a03c-4e6a985c714f | 2026-01-07 | Warnings, Adverse reactions | ANDA040284 994521 X0A40N8I4S |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.